As I have posted before, metformin has other uses other than its antihyperglycemic effects,
Metformin Beyond Diabetes: Pleiotropic Benefits of Metformin in Attenuation of Atherosclerosis

Figure 8. Schematic proposed model for the mechanisms underlying vasculoprotective roles of metformin. By disrupting AT1R, metformin can attenuate many of the pathways that can lead to atherosclerosis, including the ones that can be triggered by HFD, and result in worsening vascular senescence. Moreover, perhaps through its effect on activation of AMPK, metformin can lead to weight loss by switching cells from an anabolic state to a catabolic energy consuming state. Also, some of the vasculoprotective effects of metformin can be through its effect on upregulation of SOD1, an antioxidant enzyme. (Dotted lines indicate the possibility of mediators for the presented effects of metformin.) AMPK indicates AMP kinase; AT1R, angiotensin II type 1 receptor; HFD, high‐fat diet; SOD1, superoxide dismutase‐1.
Benefits of Metformin in Attenuating the Hallmarks of Aging
"Recently, metformin’s extraordinary ability as a gerotherapeutic is estab-
lished through several experimental, clinical, and observational
evidence (Novelle et al. 2016; Piskovatska et al., 2019; Gloss-
mann and Lutz, 2019; Soukas et al., 2019). Moreover, in older
human adults, we recently demonstrated metformin’s efficacy
in targeting multiple age-associated metabolic and non-meta-
bolic pathways and reverting derangements, using cardiometa-
bolic and transcriptomic outcomes (Kulkarni et al., 2018).